Gounder, MrinalAbdul Razak, Albiruni RGilligan, Adrienne MLeong, HoyeeMa, XiwenSomaiah, NeetaChawla, Sant PMartin-Broto, JavierGrignani, GiovanniSchuetze, Scott MVincenzi, BrunoWagner, Andrew JChmielowski, BartoszJones, Robin LShah, JatinShacham, SharonKauffman, MichaelRiedel, Richard FAttia, Steven2023-02-092023-02-092021-04-15http://hdl.handle.net/10668/17582Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/advanced liposarcomapainpatient-reported outcomesprogression-free survivalquality of lifeselective inhibitor of nuclear exportselinexorAdultAgedAged, 80 and overCancer PainCross-Over StudiesFemaleHumansHydrazinesLiposarcomaMaleMiddle AgedNeoplasm StagingPlacebosQuality of LifeTriazolesresearch article33855868open access10.2217/fon-2021-02841744-8301PMC9344436https://doi.org/10.2217/fon-2021-0284https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344436/pdf